Your browser doesn't support javascript.
loading
The Enterprise stent…still useful after all these years.
El Naamani, Kareem; Syal, Amit; Field, Nicholas C; Teichner, Eric M; Ghanem, Marc; Herial, Nabeel A; Tjoumakaris, Stavropoula I; Jabbour, Pascal; Rosenwasser, Robert H; Paul, Alexandra R; Gooch, M Reid.
Afiliación
  • El Naamani K; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Syal A; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Field NC; Department of Neurosurgery, Albany Medical Center, Albany, New York, USA.
  • Teichner EM; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Ghanem M; School of Medicine, Lebanese American University, Beirut, Lebanon.
  • Herial NA; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Tjoumakaris SI; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Jabbour P; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Rosenwasser RH; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Paul AR; Department of Neurosurgery, Albany Medical Center, Albany, New York, USA.
  • Gooch MR; Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Interv Neuroradiol ; : 15910199231224004, 2023 Dec 28.
Article en En | MEDLINE | ID: mdl-38155430
ABSTRACT

BACKGROUND:

The Enterprise stent (Codman Neuro, Massachusetts, USA) received Food and Drug Administration (FDA) approval in 2007 for stent-assisted coiling (SAC). Since its introduction, newer stents and devices for aneurysm treatment have been developed resulting in a shift in the utilization of this stent from SAC to other off-label indications.

OBJECTIVE:

To describe our experience with the Enterprise stent being used for SAC and other off-label indications.

METHODS:

This is a multi-center retrospective review of the use of the Enterprise stent between 2018 and 2023. All patients in which the Enterprise stent was successfully deployed were included in the study.

RESULTS:

Our study cohort comprised of 194 patients, mostly females (n = 112, 57.7%), with a mean age of 63.2 years ± 14.3. The Enterprise stent was used for SAC in only 24 (12.4%) patients and was used for rescue stenting in stroke in 101 patients (52.1%), treatment of intracranial stenosis in 53 patients (27.3%), treatment of in-stent stenosis in 1 patient (0.5%), and for treatment of dissections in 15 patients (7.7%). From 2018 to 2023, the use of Enterprise stents for SAC significantly decreased (p < 0.0001) while the use of Enterprise stents for non-SAC purposes was insignificantly variable (p = 0.05).

CONCLUSION:

Our study shows that the Enterprise stent remains a reliable tool in neuroendovascular procedures, even if its original intended use has been supplanted by other devices.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Interv Neuroradiol Asunto de la revista: NEUROLOGIA / RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Interv Neuroradiol Asunto de la revista: NEUROLOGIA / RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos